Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 9/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.36 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.36 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.36 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.36 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4143743 | 0.84 | HSD11B1 (0.49) | HSD11B1PIK3CDKDM4EALDH1A1POLB | |
| SCHEMBL4132317 | 0.81 | PIK3CD (0.56) | HSD11B1PIK3CDKDM4EALDH1A1POLB | |
| SCHEMBL4131816 | 0.80 | PIK3CD (0.63) | HSD11B1PIK3CDKDM4EALDH1A1POLB | |
| SCHEMBL4141107 | 0.79 | PIK3CD (0.65) | HSD11B1PIK3CDKDM4EALDH1A1POLB | |
| SCHEMBL4141427 | 0.79 | PIK3CD (0.65) | HSD11B1PIK3CDKDM4EALDH1A1POLB | |
| SCHEMBL4134742 | 0.79 | PIK3CD (0.65) | HSD11B1PIK3CDKDM4EALDH1A1POLB | |
| SCHEMBL4141303 | 0.78 | PIK3CD (0.48) | HSD11B1PIK3CDKDM4EALDH1A1POLB | |
| SCHEMBL5203258 | 0.75 | PIK3CD (0.55) | HSD11B1PIK3CDABL1BCRPTPN11 | |
| SCHEMBL4140191 | 0.74 | POLB (0.47) | HSD11B1PIK3CDKDM4EALDH1A1POLB | |
| SCHEMBL4143896 | 0.73 | PIK3CD (0.48) | HSD11B1PIK3CDKDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227587-A1 | Pyrimidines as inhibitors of phosphoinositide-3-kinases (PI3K) | WARNER-LAMBERT COMPANY LLC | 2009-09-10 | — | — | US | claimed |
| EP-1682532-B1 | PYRIMIDINES AS INHIBITORS OF PHOSPHOINOSITIDE-3-KINASES (PI3K) | WARNER LAMBERT CO (US) | 2007-06-27 | — | — | EP | claimed |
| US-20090227587-A1 | Pyrimidines as inhibitors of phosphoinositide-3-kinases (PI3K) | WARNER-LAMBERT COMPANY LLC | 2009-09-10 | — | — | US | disclosed |
| EP-1682532-B1 | PYRIMIDINES AS INHIBITORS OF PHOSPHOINOSITIDE-3-KINASES (PI3K) | WARNER LAMBERT CO (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1682532-A1 | PYRIMIDINES AS INHIBITORS OF PHOSPHOINOSITIDE-3-KINASES (PI3K) | Warner-Lambert Company LLC (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005042519-A1 | PYRIMIDINES AS INHIBITORS OF PHOSPHOINOSITIDE -3-KINASES (PI3K) | WARNER-LAMBERT COMPANY LLC (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227587-A1 | Pyrimidines as inhibitors of phosphoinositide-3-kinases (PI3K) | PIK3CA, PIK3CD, PIK3R5 | HSD11B1 1796/4885PIK3CD 2/4885KDM4E 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.